Evidence map›Paper›PMID 40097239›Full record

ArticlemAbs2025

A novel

Yihan Li, Rosendo Villafuerte-Vega, Vikram M Shenoy, Heidi M Jackson, Yuting Wang, Karen E Parrish, Gary J Jenkins, Hetal Sarvaiya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yihan LiDepartment of Quantitative, Translational & ADME Sciences, AbbVie, South San Francisco, CA, USA.
Rosendo Villafuerte-VegaDepartment of Chemistry, University of Michigan, Ann Arbor, MI, USA.
Vikram M ShenoyDepartment of Quantitative, Translational & ADME Sciences, AbbVie, South San Francisco, CA, USA.
Heidi M JacksonDepartment of Quantitative, Translational & ADME Sciences, AbbVie, Worcester, MA, USA.
Yuting WangDepartment of Quantitative, Translational & ADME Sciences, AbbVie, Worcester, MA, USA.
Karen E ParrishDepartment of Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, IL, USA.
Gary J JenkinsDepartment of Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, IL, USA.
Hetal SarvaiyaDepartment of Quantitative, Translational & ADME Sciences, AbbVie, South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-based therapeutics have demonstrated remarkable therapeutic benefit, but their susceptibility to biotransformation and degradation in the body can affect their safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) profiles.

Indexed as

Antibodies, BispecificAntibodies, MonoclonalAnimalsChromatography, LiquidDrug StabilityHumansMass SpectrometryProtein StabilityReference StandardsAntibodies, BispecificAntibodies, Monoclonalinternal standardIn vitro serum stabilityLC-MSmonoclonal and bispecific antibodiestranslation from in vitro to in vivo

Identifiers

PMID40097239
PMCPMC11917174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.